EQUTY INVESTMENT (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended |
|---|---|---|
Dec. 18, 2018 |
Dec. 31, 2019 |
|
| SHARE OF NET LOSSES OF EQUITY METHOD INVESTEE | $ (604,000) | |
| Equity Method Goodwill | 5,041,000 | |
| ILiAD [Member] | ||
| Advisory and legal expenses | $ 41,000 | |
| ILiAD [Member] | Warrant [Member] | ||
| Units purchase | 366,666 | |
| Price per unit | $ 2.75 | |
| ILiAD [Member] | Tranche One [Member] | ||
| Initial investment | $ 2,500,000 | |
| Description for the terms of allowed-to-proceed notice under aggrement | May 2, 2019 that it had received an “allowed to proceed” notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitment such that 40% would be currently due ($1,000,000 paid by the Company on May 6, 2019) and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD received satisfactory safety data from the clinical study. On August 9, 2019, ILiAD notified us that the FDA has allowed Phase 2b trial to proceed to full enrollment based on satisfactory safety data from the first phase of the clinical study which triggered our additional $1,500,000 investment. The Phase 2b trial is fully enrolled and preliminary immunological data is anticipated to be received by ILiAD by April 2020. At December 31, 2019, we owned approximately 10.3% of the outstanding units of ILiAD (on a non-fully diluted basis). | |
| ILiAD [Member] | Tranche Two [Member] | ||
| Initial investment | $ 2,500,000 | |
| ILiAD [Member] | Class C units [Member] | ||
| Ownership percentage | 10.30% | |
| ILiAD [Member] | Class C units [Member] | Tranche One [Member] | ||
| Units purchase | 1,111,111 | |
| Price per unit | $ 2.25 | |
| ILiAD [Member] | Class C units [Member] | Tranche Two [Member] | ||
| Units purchase | 943,396 | |
| Price per unit | $ 2.65 | |
| Warrants to purchase units | 311,320 | |
| Exercise price | $ 3.50 | |
| ILiAD [Member] | Maximum [Member] | ||
| Investment | $ 5,000,000 | |
| ILiAD [Member] | Maximum [Member] | Class C units [Member] | ||
| Investment | $ 14,500,000 |